Insulet's Q2 2026 Revenue Surges 23.5% on Strong International Growth
Event summary
- Insulet reported Q2 2026 revenue of $801.7 million, up 23.5% year-over-year.
- International Omnipod revenue grew 35.5%, outpacing U.S. growth of 20.1%.
- Adjusted operating income rose to $154.5 million, a 19.3% margin.
- Launched Omnipod 5 and Omnipod Discover in Spain, expanding to 26 countries.
- Updated FY 2026 guidance: Total revenue growth now expected at 20-22%.
The big picture
Insulet's strong Q2 performance highlights the growing global demand for tubeless insulin delivery systems. The company's ability to expand margins while scaling internationally positions it favorably against competitors in the automated insulin delivery space. However, sustaining this growth will require navigating regulatory hurdles and maintaining technological innovation.
What we're watching
- International Scaling
- Whether Insulet can sustain its 35.5% international growth rate amid currency fluctuations and local market dynamics.
- Type 2 Diabetes Expansion
- How the EVOLUTION 3 study results will impact adoption of Omnipod for type 2 diabetes patients.
- Competitive Positioning
- The pace at which Insulet can differentiate itself from traditional insulin pump manufacturers through its tubeless technology.